Idorsia Invites Bondholders to Essential Meetings for Future Growth
Ad hoc announcement pursuant to Art. 53 LR
Upcoming Bondholder Meetings
Bondholder meetings are scheduled for a Wednesday, where significant proposals concerning the two existing convertible bonds, CB 2025 and CB 2028, will be voted on. This initiative is crucial as the management seeks to amend the terms impacting these financial instruments.
Company Announcement Regarding Bondholder Meetings
Idorsia Ltd (SIX: IDIA) has announced the issuance of invitations for the upcoming bondholder meetings. These meetings aim to gather feedback on the proposed amendments to the two convertible bonds totaling CHF 800 million, with maturities in 2025 and 2028. This follows the expiration of the appeal period for the previously approved term adjustments associated with the CB 2025 bondholder meeting.
Holistic Restructuring Proposals
During the bondholder meetings, the company will propose necessary alterations to the current terms of the CB 2025 and CB 2028 bonds aimed at enhancing the organization's financial structure. This effort is part of a larger holistic restructuring strategy, which reflects a commitment to sound financial management and the long-term sustainability of the company.
Support from Bondholders
A substantial number of bondholders have already shown their commitment to the proposed changes. Reports indicate that as many as 87% of CB 2025 holders and 90% of CB 2028 holders are in support of these amendments through legally binding agreements. Such support is pivotal for the company's pursuit of a reorganized structure to benefit all stakeholders.
Amendments to the bonds' terms will be contingent upon the successful completion of an exchange offer that is anticipated to be initiated around the time of the bondholder meetings.
Accessing Bondholder Meeting Information
Bondholders looking for comprehensive details regarding the meetings can find invitations, resolutions, and financial status reports at dedicated online resources.
About Idorsia
Idorsia Ltd is passionately focused on drug discovery and development, striving to challenge medical norms and enhance patient care. The company dreams of transforming the landscape of medicine through innovative solutions that can impact patient lives positively.
Operating out of a prominent location in Switzerland, Idorsia boasts an accomplished team of professionals committed to advancing scientific research and development. The firm is advancing its diverse portfolio, presenting therapeutics like QUVIVIQ™, designed to address insomnia, a growing health issue worldwide.
Contact Information for Inquiries
For more information, please reach out to:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com
Frequently Asked Questions
What is the purpose of the upcoming bondholder meetings?
The meetings aim to discuss and vote on proposed amendments to the terms of the CB 2025 and CB 2028 convertible bonds to restructure and strengthen the company's financial framework.
How much support have the bondholders shown for the changes?
Approximately 87% of CB 2025 holders and 90% of CB 2028 holders have indicated their support via legally binding lockup agreements.
What is the role of the exchange offer in this process?
Amendments to the bonds' terms will depend on the successful completion of an exchange offer anticipated to be launched concurrently with the bondholder meetings.
Where can bondholders access relevant meeting information?
Bondholders can find invitations, resolutions, and financial status updates on dedicated online portals outlined in the communications from Idorsia.
What are Idorsia's goals for the future?
Idorsia aims to challenge existing medical paradigms by discovering, developing, and commercializing transformative medicines, focusing on patient needs.
